Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01149837 · ClinicalTrials.gov registry record
Evaluation of InnoLIA HTLV I/II Score
A clinical trial of Human T-Lymphotrophic Virus Type I and/or Type II, sponsored by Creative Testing Solutions.
- Completed
- Registry status
- 3,305
- Enrollment target
- 1
- Study location
NCT01149837: Completed study of Human T-Lymphotrophic Virus Type I and/or Type II, sponsored by Creative Testing Solutions.
NCT01149837 is a study of Human T-Lymphotrophic Virus Type I and/or Type II that has completed, run by Creative Testing Solutions. The registered enrollment target is 3,305 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01149837, a study of Human T-Lymphotrophic Virus Type I and/or Type II, has completed, sponsored by Creative Testing Solutions.
- COMPLETED
- Registry status
- 3,305 participants
- Enrollment target
- 1
- Study location
Study Summary
The InnoLIA HTLV I/II Score is an in vitro diagnostic test for confirmation of antibodies to human T-cell lymphotropic virus (HTLV) type I and type II in human blood samples. It is intended as a supplemental test for blood donor samples that are reactive in routine anti-HTLV screening tests. This study will determine if the test is useful for donor counseling purposes.
Primary Outcome
322 residual donor samples tested
Conditions Studied
Interventions
- DEVICE InnoLIA HTLV I/II Score line immunoassay
Study Locations (1)
Arizona
- Creative Testing Solutions - Tempe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,305 participants |
| Start Date | 2013-07 |
| Est. Completion | 2019-01-25 |
What the finished NCT01149837 record still lists
NCT01149837 is an observational study that tracks outcomes without assigning an intervention. Its 3,305 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Human T-Lymphotrophic Virus Type I and/or Type II appearing as the primary indexed condition, and to 1 intervention - of which InnoLIA HTLV I/II Score line immunoassay is the first listed.
NCT01149837 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT01149837 about?
NCT01149837 is a clinical study titled "Evaluation of InnoLIA HTLV I/II Score". The InnoLIA HTLV I/II Score is an in vitro diagnostic test for confirmation of antibodies to human T-cell lymphotropic virus (HTLV) type I and type II in human blood samples. It is intended as a supplemental test for blood donor samples that are reactive in routine anti-HTLV screening tests. This st...
What is the current status of trial NCT01149837?
This trial is currently completed. The enrollment target is 3,305 participants. The study started on 2013-07. Estimated completion is 2019-01-25.
What conditions does trial NCT01149837 study?
This clinical trial studies the following conditions: Human T-Lymphotrophic Virus Type I and/or Type II.
What interventions are being tested in trial NCT01149837?
The interventions under investigation include: InnoLIA HTLV I/II Score line immunoassay (DEVICE).
Who is sponsoring clinical trial NCT01149837?
This trial is sponsored by Creative Testing Solutions, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01149837 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
- NCT06543446 · 3,290 participants · NA
Comparative Effectiveness of Prophylactic ICD Versus Non-ICD Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia